Toll Free: 1-888-928-9744

Cardiac Biomarkers Market By Type (Troponin, Creatine kinase - MB (CK-MB), Natriuretic peptides - B-type Natriuretic Peptide (BNP) & N-terminal pro b-type Natriuretic peptide (NT-proBNP), Myoglobin, Ischemia Modified Albumin (IMA), Heart-type Fatty Acid Binding Protein (H-FABP), LDH isoenzymes), By Application (Acute Coronary Syndrome, Myocardial infarction, Congestive heart failure, Cardiomyopathy, Ischemia, Myocarditis, Atrial fibrillation), By End Use, By Region And Segment Forecasts to 2024

Published: Sep, 2016 | Pages: 66 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)

The cardiac biomarkers market is expected to reach USD13.3 billion by 2024, according to a new report by Grand View Research, Inc. The cardiac biomarkers market is anticipated to witness a lucrative growth during the forecast period from 2016 to 2024. Analysis of global market trends focuses on the increasing demand for cardiac biomarkers owing to its increased adoption in cardiovascular disease diagnosis. Furthermore, this growth is attributed to a majority of factors, such as the high prevalence of Acute Coronary Syndrome (ACS), continual technological advancements in the development of cardiovascular biomarkers, increasing number of new product launches by the key market players, rising demand for point of care cardiac testing kits, along with the high specificity and sensitivity of these biomarkers in the detection of cardiovascular diseases, especially acute myocardial infarction.

The cardiac biomarkers market has been classified by type into troponin, Creatine kinase-MB(CK-MB), B-type Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP), myoglobin, and others. Troponin is a heteromeric protein and comprises cardiac troponin T & I, which are abbreviated as cTnT & cTnI, respectively. The troponin biomarkers segment is expected to grow lucratively in the forecast period at a significant CAGR. The diagnostic efficiency and specificity related to cardiac biomarker testing renders it a universally gold standard test to diagnose cardiovascular disorders worldwide. The market by application is segmented into acute coronary syndrome, myocardial infarction, congestive heart failure, and others. ACS is expected to be the highest grossing segment according to the study. ACS is responsible for huge medical costs globally and is responsible for most hospital readmission cases. The increasing efforts to cut down worldwide ACS prevalence rates are expected to drive the growth of the biomarkers market.

The key countries included in the report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa, and the Middle East. North America accounted for the largest market in 2015, whereas the Asia Pacific region is anticipated to be the fastest growing region during the forecast period.

Further key findings from the study suggest:

North America is estimated to dominate the global cardiac biomarkers market. The high prevalence of coronary heart disease in western countries is one of the major factors contributing to the high demand for cardiac biomarker diagnostics.

The Asia Pacific region is anticipated to be the fastest growing region in the study period owing to the large population, especially in China and India. Apart from that, there exists a high prevalence rate of myocardial infarction in the region. This prevalence rate is expected to fuel the demand for cardiac biomarker diagnostics.

The troponin biomarker segment is expected to grow at a significant rate, and is expected to grow at the highest CAGR compared to others and accounts for the largest market share in 2015.

The sector comprises of several local as well as global players. Some of the major players of this vertical include Alere, Inc., Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, and bioMerieux SA.
 Table of Contents
Chapter 1. Methodology and Scope Chapter 2. Executive Summary Chapter 3. Market Snapshot Chapter 4. Market Variables, Trends & Scope 4.1. Market segmentation & scope 4.2. Cardiac biomarkers: Market dynamics 4.2.1. Market driver analysis 4.2.2. Market restraint analysis 4.3. Penetration & growth prospect mapping 4.4. Cardiac Biomarkers - SWOT Analysis, By Factor (political & legal, economic and technological) 4.5. Industry Analysis - Porter's 4.6. Cardiac Biomarkers Market: Company Market Share Analysis, 2015 Chapter 5. Market Categorization 1: Cardiac Biomarkers Type Estimates & Trend Analysis 5.1. Cardiac Biomarkers Market: Type Movement Analysis 5.2. Troponin 5.2.1. Market estimates and forecasts, 2013 - 2024 (USD Million) 5.3. CK-MB 5.3.1. Market estimates and forecasts, 2013 - 2024 (USD Million) 5.4. Natriuretic Peptides (BNP and NT-proBNP) 5.4.1. Market estimates and forecasts, 2013 - 2024 (USD Million) 5.5. Myoglobin 5.5.1. Market estimates and forecasts, 2013 - 2024 (USD Million) 5.6. Others 5.6.1. Market estimates and forecasts, 2013 - 2024 (USD Million) Chapter 6. Market Categorization 2: Cardiac Biomarkers Application Estimates & Trend Analysis 6.1. Cardiac Biomarkers Market: Application Movement Analysis 6.2. Acute Myocardial Infarction (AMI) 6.2.1. Market estimates and forecasts, 2013 - 2024 (USD Million) 6.3. Congestive Heart Failure (CHF) 6.3.1. Market estimates and forecasts, 2013 - 2024 (USD Million) 6.4. Acute Coronary Syndrome (ACS) 6.4.1. Market estimates and forecasts, 2013 - 2024 (USD Million) 6.5. Others 6.5.1. Market estimates and forecasts, 2013 - 2024 (USD Million) Chapter 7. Market Categorization 3: Cardiac Biomarkers End-use Estimates & Trend Analysis 7.1. Cardiac Biomarkers Market: End-use Movement Analysis 7.2. Laboratory Testing 7.2.1. Market estimates and forecasts, 2013 - 2024 (USD Million) 7.3. Point of Care Testing 7.3.1. Market estimates and forecasts, 2013 - 2024 (USD Million) Chapter 8. Cardiac biomarkers: Regional Estimates & Trend Analysis, by Type, Application, & End-use 8.1. Cardiac biomarkers Market Share (%) Analysis, by Region, 2016 & 2024 8.2. North America 8.2.1. U.S. 8.2.1.1. U.S. Cardiac biomarkers market, by type, 2013 - 2024 (USD Million) 8.2.1.2. U.S. Cardiac biomarkers market, by application, 2013 - 2024 (USD Million) 8.2.1.3. U.S. Cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million) 8.2.2. Canada 8.2.2.1. Canada Cardiac biomarkers market, by type, 2013 - 2024 (USD Million) 8.2.2.2. Canada Cardiac biomarkers market, by application, 2013 - 2024 (USD Million) 8.2.2.3. Canada Cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million) 8.3. Europe 8.3.1. Germany 8.3.1.1. Germany Cardiac biomarkers market, by type, 2013 - 2024 (USD Million) 8.3.1.2. Germany Cardiac biomarkers market, by application, 2013 - 2024 (USD Million) 8.3.1.3. Germany Cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million) 8.3.2. UK 8.3.2.1. UK Cardiac biomarkers market, by type, 2013 - 2024 (USD Million) 8.3.2.2. UK Cardiac biomarkers market, by application, 2013 - 2024 (USD Million) 8.3.2.3. UK Cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million) 8.4. Asia Pacific 8.4.1. China 8.4.1.1. China Cardiac biomarkers market, by type, 2013 - 2024 (USD Million) 8.4.1.2. China Cardiac biomarkers market, by application, 2013 - 2024 (USD Million) 8.4.1.3. China Cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million) 8.4.2. India 8.4.2.1. India Cardiac biomarkers market, by type, 2013 - 2024 (USD Million) 8.4.2.2. India Cardiac biomarkers market, by application, 2013 - 2024 (USD Million) 8.4.2.3. India Cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million) 8.5. Latin America 8.5.1. Brazil 8.5.1.1. Brazil cardiac biomarkers market, by type, 2013 - 2024 (USD Million) 8.5.1.2. Brazil cardiac biomarkers market, by application, 2013 - 2024 (USD Million) 8.5.1.3. Brazil cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million) 8.5.2. Mexico 8.5.2.1. Mexico cardiac biomarkers market, by type, 2013 - 2024 (USD Million) 8.5.2.2. Mexico cardiac biomarkers market, by application, 2013 - 2024 (USD Million) 8.5.2.3. Mexico cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million) 8.6. Middle East Africa 8.6.1. South Africa 8.6.1.1. South Africa cardiac biomarkers market, by type, 2013 - 2024 (USD Million) 8.6.1.2. South Africa cardiac biomarkers market, by application, 2013 - 2024 (USD Million) 8.6.1.3. South Africa cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million) 8.6.2. Middle East 8.6.2.1. Middle East cardiac biomarkers market, by type, 2013 - 2024 (USD Million) 8.6.2.2. Middle East cardiac biomarkers market, by application, 2013 - 2024 (USD Million) 8.6.2.3. Middle East cardiac biomarkers market, by end-use, 2013 - 2024 (USD Million) Chapter 9. Competitive Landscape 9.1. Company Profiles 9.1.1. Abbott Laboratories 9.1.1.1. Company Overview 9.1.1.2. Financial Performance 9.1.1.3. Product Benchmarking 9.1.1.4. Strategic Initiatives 9.1.2. Alere, Inc. 9.1.2.1. Company Overview 9.1.2.2. Financial Performance 9.1.2.3. Product Benchmarking 9.1.2.4. Strategic Initiatives 9.1.3. Siemens Healthcare GmbH 9.1.3.1. Company Overview 9.1.3.2. Financial Performance 9.1.3.3. Product Benchmarking 9.1.3.4. Strategic Initiatives 9.1.4. Roche Diagnostics Corporation 9.1.4.1. Company Overview 9.1.4.2. Financial Performance 9.1.4.3. Product Benchmarking 9.1.4.4. Strategic Initiatives 9.1.5. Beckman Coulter, Inc. 9.1.5.1. Company Overview 9.1.5.2. Financial Performance 9.1.5.3. Product Benchmarking 9.1.5.4. Strategic Initiatives 9.1.6. Becton, Dickinson &Co. 9.1.6.1. Company Overview 9.1.6.2. Financial Performance 9.1.6.3. Product Benchmarking 9.1.6.4. Strategic Initiatives 9.1.7. Thermo Fisher Scientific, Inc. 9.1.7.1. Company Overview 9.1.7.2. Financial Performance 9.1.7.3. Product Benchmarking 9.1.7.4. Strategic Initiatives 9.1.8. bioMérieux SA 9.1.8.1. Company Overview 9.1.8.2. Financial Performance 9.1.8.3. Product Benchmarking 9.1.8.4. Strategic Initiatives 9.1.9. Bio-Rad Laboratories, Inc. 9.1.9.1. Company Overview 9.1.9.2. Financial Performance 9.1.9.3. Product Benchmarking 9.1.9.4. Strategic Initiatives 9.1.10. BG Medicines 9.1.10.1. Company Overview 9.1.10.2. Financial Performance 9.1.10.3. Product Benchmarking 9.1.10.4. Strategic Initiatives
List of Tables
1. Cardiac biomarkers market - Industry Snapshot & Key Buying Criteria, 2013 - 2024 2. Cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 3. Cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 4. Cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 5. Cardiac biomarkers market, by region, 2013 - 2024 (USD Million) 6. Cardiac biomarkers- Key Market Driver Analysis 7. Cardiac biomarkers- Key Market Restraint Analysis 8. North America cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 9. North America cardiac biomarkers market revenue, by application type, 2013 - 2024 (USD Million) 10. North America cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 11. U.S. cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 12. U.S. cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 13. U.S. cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 14. Canada cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 15. Canada cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 16. Canada cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 17. Europe cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 18. Europe cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 19. Europe cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 20. Germany cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 21. Germany cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 22. Germany cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 23. UK cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 24. UK cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 25. UK cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 26. Asia Pacific cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 27. Asia Pacific cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 28. Asia Pacific cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 29. China cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 30. China cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 31. China cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 32. India cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 33. India cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 34. India cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 35. Brazil cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 36. Brazil cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 37. Brazil cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 38. Mexico cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 39. Mexico cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 40. Mexico cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 41. MEA cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 42. MEA cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 43. MEA cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 44. South Africa cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 45. South Africa cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 46. South Africa cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million) 47. Middle East cardiac biomarkers market revenue, by type, 2013 - 2024 (USD Million) 48. Middle East cardiac biomarkers market revenue, by application, 2013 - 2024 (USD Million) 49. Middle East cardiac biomarkers market revenue, by end-use, 2013 - 2024 (USD Million)



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $4250
Multi User - US $5250
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify